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OBJECTIVE — The study aim was to determine if multisystemic therapy (MST), an intensive
home-basedpsychotherapy,couldreducehospitaladmissionsfordiabeticketoacidosis(DKA)in
youth with poorly controlled type 1 diabetes over 24 months. Potential cost savings from
reductions in admissions were also evaluated.
RESEARCHDESIGNANDMETHODS — Atotalof127youthwererandomlyassigned
to MST or control groups and also received standard medical care.
RESULTS — Youth who received MST had signiﬁcantly fewer hospital admissions than con-
trolsubjects(
211.77,4d.f.,n127;P0.019).MST-treatedyouthhadsigniﬁcantlyfewer
admissionsversustheirbaselinerateat6-month(P0.004),12-month(P0.021),18-month
(P  0.046), and 24-month follow-up (P  0.034). Cost to provide MST was 6,934 USD per
youth; however, substantial cost offsets occurred from reductions in DKA admissions.
CONCLUSIONS — The study demonstrates the value of intensive behavioral interventions
for high-risk youth with diabetes for reducing one of the most serious consequences of medica-
tion noncompliance.
Diabetes Care 31:1746–1747, 2008
W
e have previously reported on
multisystemictherapy(MST),an
intensive home-based family
therapy, for youth with chronically poor
metabolic control (CPMC). MST pro-
duced improvements in metabolic con-
trol and reducted indicators of serious
nonadherence(DKAhospitaladmissions)
at treatment termination (1,2). Reduc-
tions in admissions were maintained 6
monthslater(2).Thepresentstudyinves-
tigated the effects of MST on DKA admis-
sions at the conclusion of the trial and
related cost savings.
RESEARCH DESIGN AND
METHODS— A total of 127 adoles-
cents with CPMC and their families were
recruited from endocrinology clinics at
Children’s Hospital of Michigan between
1999 and 2004. Eligible youth were diag-
nosed with type 1 diabetes for at least 1
year, had an average A1C of 8% during
theyearbeforestudyentry,andwereaged
10–17 years. Mean  SD A1C at study
entry was 11.3  2.3%. A total of 92% of
thesubjectsusedinjectedinsulin,and8%
used insulin pumps. Mean  SD age was
13.22.0years,and63%ofparticipants
were African American.
A total of 64 participants were ran-
domly assigned to MST and 63 to a control
group. All families received quarterly visits
with a multidisciplinary diabetes team.
MST-treatment families also received 6
months of therapy (mean 5.7 months).
Familieswerefollowedfor24monthstotal.
MST targeted adherence-related problems
within the family and broader community
systems (1,3). These systems included fam-
ily (e.g., poor parental supervision and
oversight of the youth’s diabetes care com-
pletion), school (e.g., inadequate commu-
nication between parents and school
personnel regarding the youth’s health
needs), and health care system factors (e.g.,
barrierstokeepingclinicappointmentsdue
to problems with transportation or family
disorganization).
The number of DKA admissions was
obtained from the treating hospital’s in-
formation system for the 6-month win-
dow before study entry (baseline [T1])
and for the follow-up periods (baseline to
6months[T2],6–12months[T3],12–18
months [T4], and 18–24 months [T5]).
Criteria used to diagnose DKA were hy-
perglycemia (blood glucose 16.65
mmol/l),serumacetonepositiveatgreater
than 1:2 dilution of serum, acidosis (pH
7.30andbicarbonate15mmol/l),ke-
tonuria, and glucosuria.
As decreases in A1C at treatment
terminationforMST-treatedyouthwere
not maintained at 6 months (2), cost-
effectiveness evaluation was not appro-
priate. Cost savings were evaluated by
reductions in admissions. A total of 45
youth (21 MST-treated and 24 control
subjects) had at least one admission
during the study. Costs were estimated
by obtaining direct hospital costs and
revenues from the hospital ﬁnancial da-
tabase and calculating an average cost
for DKA admissions during the study.
Revenues reﬂected third-party payor
reimbursements.
Costs of MST for youth with CPMC
were estimated from MST costs in the “real
world” rather than costs in the trial, which
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costs. Because MST as originally developed
for delinquent youth is widely dissemi-
nated, real-world estimates could be calcu-
lated. Costs included salary and beneﬁts;
overhead for therapists, supervisors, and
program staff; therapist mileage; travel for
training; MST licensing fees; and quality as-
surance costs. Costs per youth were esti-
mated at 6,934 USD.
RESULTS— Figure 1 shows cumula-
tive DKA admissions for MST-treated and
control youth. Change in admission fre-
quency over the 24-month trial was evalu-
ated using repeated-measures Poisson
regression. Analyses were performed with
generalized estimating equations by speci-
fying the Poisson distribution for the re-
sponse variable (4,5); this accounted for
correlated error. Time effects were parti-
tionedintotime-orderedcontrastscompar-
ingT1witheachfollow-upperiod(T2–T5).
The effects of MST were evaluated by the
group time interaction, followed by sim-
ple effect tests of MST within-group
changes from baseline. Single-parent status
wasusedasacovariateduetoitsrelatedness
to outcome in prior studies. The
group  time interaction was signiﬁ-
cant (
2  11.77, 4 d.f., n  127; P 
0.019),indicatingMST-treatedyouthhad
signiﬁcantly fewer admissions than con-
trol subjects. Simple effect contrasts
showed that MST youth had signiﬁcantly
fewerDKAadmissionsrelativetobaseline
frequency at T2 (P  0.004), T3 (P 
0.021), T4 (P  0.046), and T5 (P 
0.034). Drops in admissions per youth
were obtained over constant 6-month
intervals and, hence, are measures of ef-
fect size when expressed as rates. The
rates were 0.31 (95% CI 0.09–0.54),
0.27 (0.03–0.50), 0.23 (0.01–0.47), and
0.23 (0.01–0.47) for T2–T5, respec-
tively. Control subjects had fewer admis-
sions only at T5 (P  0.026); rate 0.24
(0.02–0.45).
Hospitaldirectcostswere4,237USD,
and revenues were 5,446 USD per admis-
sion. The 24 control youth with any ad-
mission in 24 months had 85 DKA
admissions. The 21 MST-treated youth
had 45 admissions. Hence, DKA admis-
sions resulted in 360,145 and 190,665
USD in hospital costs and 462,910 and
245,070 USD in third-party payor costs
for control and MST-treated youth, re-
spectively. Costs to provide MST for 21
youth were estimated at 145,614 USD
(21  6,943). Therefore, MST was esti-
matedtopotentiallysaveatotalof23,886
(institutional perspective) or 72,226
(third-party payor perspective) USD.
CONCLUSIONS— MST produced
lasting reductions in postdiagnostic DKA
hospital admissions, which occur most
commonly due to insulin noncompliance
(6,7).ReducedadmissionsratesintheMST
group at follow-up were consistent with
those reported in recent general population
studies of youth with diabetes (8). The only
other intervention with effects on DKA in
youth with CPMC is residential psychiatric
treatment(9),acostlyinterventionwithun-
known long-term impact. Costs to provide
MST to youth with CPMC were relatively
high.However,preliminaryevaluationsug-
gests that control youth with DKA admis-
sions accumulated sufﬁcient costs over 24
monthsandthatexpendituresonMSTmay
be justiﬁed by potential for savings. MST
couldproducecostsavingsforthesubsetof
youth with CPMC and a recent history of
DKA admissions if admissions are occur-
ringfrequently.Thestudydemonstratesthe
potential for intensive behavioral interven-
tions to reduce serious consequences of
medication noncompliance in high-risk
youth.
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Figure 1—Cumulative number of DKA admissions during ﬁve 6-month intervals for MST ()
and control () participants. The baseline interval (T1) started 6 months before trial entry; the
subsequent intervals were from T1 to treatment termination (T2), from treatment termination to
12-month follow-up (T3), from 12-month to 18-month follow-up (T4), and from 18-month to
24-month follow-up (T5). Error bars are  1 SE.
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